Ovarian endometrioid carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:31:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ovarian endometrioid carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Testing TUB-040 Combined with Standard Cancer Drugs for Patients with High-Grade Epithelial Serous or Endometrioid Ovarian Cancer https://clinicaltrials.eu/trial/a-study-testing-tub-040-combined-with-standard-cancer-drugs-for-patients-with-high-grade-epithelial-serous-or-endometrioid-ovarian-cancer/ Thu, 30 Apr 2026 13:08:43 +0000 https://clinicaltrials.eu/trial/a-study-testing-tub-040-combined-with-standard-cancer-drugs-for-patients-with-high-grade-epithelial-serous-or-endometrioid-ovarian-cancer/ This study involves patients with high-grade epithelial serous or endometrioid epithelial ovarian cancer, which are types of cancer that begin in the ovaries, fallopian tubes, or the lining of the abdomen. The study will test a new medication called TUB-040, which is given through a vein as an intravenous infusion. This medication will be used together with standard drugs that are commonly used to treat ovarian cancer. The purpose of this study is to find out if TUB-040 is safe and well-tolerated when combined with standard ovarian cancer treatments, and to determine the highest dose that can be given without causing serious side effects. The study will also look at how well this combination works in treating the cancer.

During the study, patients will receive TUB-040 along with standard chemotherapy drugs. The medication is designed to target specific features of cancer cells. Doctors will monitor patients closely to check for any unwanted effects or side effects that may occur during treatment. Blood tests and other medical evaluations will be done regularly to check how the body is responding to the treatment and to measure the levels of the medication in the blood. Scans will be performed to see if the tumors are getting smaller or if the cancer is staying stable. The study will also collect tumor tissue samples to examine certain markers in the cancer cells that might help predict how well the treatment will work.

The study will measure several outcomes including the number and severity of side effects that patients experience, how the medication moves through the body, and whether the body develops an immune response to the medication. Doctors will also assess how many patients respond to the treatment, how long it takes for the cancer to respond, how long the response lasts, and how long patients live without their cancer getting worse. Additional measurements will include changes in a blood marker called CA-125, which is often used to monitor ovarian cancer. Patients who join this study will have already received previous treatments for their ovarian cancer and their cancer will have come back or progressed after earlier therapy.

]]>